ScienceDaily
•80% Informative
New study shows FDA-approved trametinib and entinostat can be given in tandem to produce fewer tumors in mice with LKB1-mutated NSCLC.
The findings may lead to clinical trials to test the new regimen in humans.
The discovery could have potential applications in lymphoma, melanoma, and pancreatic cancer.
The work was supported by the National Institutes of Health (R35CA220538, P01CA120964, K22CA251636, 5T32CA009370, 5F32CA206400, CCSG P30CA014195, and CCSG P30CA23100), Leona M. and Harry B. Helmsley Charitable Trust (#2012-PG-MED002), American Cancer Society (PF-15-037-01-DMC), and Chapman Foundation. Story Source: Journal Reference: Cite This Page:.
VR Score
91
Informative language
98
Neutral language
57
Article tone
formal
Language
English
Language complexity
61
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links